This phase I study is assessing how safe and effective a new targeted therapy (ABBV-155) is alone, or in combination with chemotherapy (paclitaxel or docetaxel), in people with small cell lung cancer, non-small cell lung cancer or breast cancer.
This trial is treating patients with small cell lung cancer, non-small cell lung cancer and HR-positive/HER2-negative breast cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
This study has two parts: Dose Escalation (Part 1) and Dose Expansion (Part 2). Part 1 is complete, and the study is now recruiting for Part 2.
Part 2 has two cohorts. Cohort 2a will enrol participants with relapsed or refractory (R/R) small cell lung cancer (SCLC), and these participants will receive ABBV-155 as monotherapy (via IV). Cohort 2b will enrol both people R/R non-small cell lung cancer (NSCLC) or people with breast cancer, who will receive ABBV-155 plus a taxane (paclitaxel or docetaxel) (via IV).
Recruiting Hospitals Read More